Collectively, we conclude our preclinical studies, along with others, support the concept that targeting STn with a highly specific antibody-drug conjugate where there is evidence of STn present in either circulation and/or the tumor, might be a viable clinical option for treatment of OvCa. This evidence concerns the gene EEF1A2 and neoplasm.